Suven Life Sciences is currently trading at Rs. 174.00, up by 1.45 points or 0.84% from its previous closing of Rs. 172.55 on the BSE.
The scrip opened at Rs. 172.00 and has touched a high and low of Rs. 176.10 and Rs. 172.00 respectively. So far 7792 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 221.00 on 21-Jul-2016 and a 52 week low of Rs. 151.10 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 177.90 and Rs. 170.45 respectively. The current market cap of the company is Rs. 2214.72 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 7.24% and 32.76% respectively.
Suven Life Science is exhibiting and presenting several exciting new results and data presentations from Suven’s portfolio of investigational neuroscience New Chemical Entities (NCEs) are being presented at Alzheimer's Association International Conference (AAIC) being held in London, England starting July 16th to 19th, 2017.
AAIC is the world's largest conference of its kind, where thousands of international investigators, clinicians, researchers and care providers will gather to share the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: